9 recruiting, 2 active not recruiting, 2 withdrawn, 1 completed. 7 Phase 2, 6 Phase 1, 2 Not applicable, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 6, Withdrawn 1 |
| Phase 1 | 6 | Recruiting 3, Active not recruiting 1, Completed 1, Enrolling by invitation 1 |
| Not applicable | 2 | Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow High-Risk Neuroblastoma: new trials by email Literature Review of High-Risk Neuroblastoma trials Research Report on High-Risk Neuroblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 Naxitamab - High-Risk Neuroblastoma | Phase 2 | Recruiting | Shaare Zedek Medical Center | 10 | 2026-06-23 | 2026-09-17 |
| A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients hu1418K322A + Temozolomide + Irinotecan - High-Risk Neuroblastoma | Phase 2 / Phase 3 | Recruiting | Renaissance Pharma Ltd. | 144 | 2026-03-30 | 2026-10-21 |
| Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma EB-DTNB-NK, Fludarabine, Cyclophosphamide - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-03-30 |
| PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma PHOX2B PC-CAR T Cells - Refractory Neuroblastoma, Relapsed Neuroblastoma | Phase 1 | Active not recruiting | Stephan Grupp MD PhD | 38 | 2025-06-20 | 2026-07-01 |
| Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma RISE Intervention - Neuroblastoma, High-risk Neuroblastoma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 84 | 2025-04-30 | 2026-02-10 |
| Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma Autologous hALK.CAR T cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Roberto Chiarle | 42 | 2025-01-31 | 2025-12-26 |
| Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors High-risk Neuroblastoma | Active not recruiting | St. Jude Children's Research Hospital | 34 | 2024-10-21 | 2026-05-13 | |
| PediCARE Health Equity Intervention in High-Risk Neuroblastoma PediCARE Intervention - Neuroblastoma, High-risk Neuroblastoma | Not applicable | Withdrawn | Dana-Farber Cancer Institute | 2024-09-01 | 2024-08-05 | |
| Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Defibrotide - Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma | Phase 2 | Withdrawn | University of California, San Francisco | 2024-08-01 | 2024-08-07 | |
| N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma DANYELZA, Sargramostim, Cytoxan - High-risk Neuroblastoma, Neuroblastoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2024-07-22 | 2026-08-28 |
| A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma OPT-821 (QS-21), oral β-glucan - Neuroblastoma, High-risk Neuroblastoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2023-09-21 | 2026-10-14 |
| GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma GPC2 CAR T cells - Refractory Neuroblastoma, Relapsed Neuroblastoma | Phase 1 | Enrolling by invitation | Stephan Grupp MD PhD | 45 | 2023-05-23 | 2026-08-14 |
| Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma Dinutuximab Beta, 13-cis-Retinoic Acid - High-risk Neuroblastoma | Phase 1 | Completed | BeiGene | 8 | 2022-06-07 | 2024-10-04 |
| Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy) - High-Risk Neuroblastoma | Phase 1 | Recruiting | Jagiellonian University | 20 | 2021-12-01 | 2022-03-09 |
| High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Vincristine, Carboplatin, Etoposide - High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 800 | 2019-11-05 | 2025-06-26 |
| Naxitamab and GM-CSF in People With Neuroblastoma Naxitamab/GM-CSF - High-Risk Neuroblastoma | No longer available | Memorial Sloan Kettering Cancer Center | 2022-12-08 |
Neuroblastoma (10) · Recurrence (2) · Financial Stress (1) · Ganglioneuroblastoma (1) · Neoplasms (1) · Retinoblastoma (1) · Thrombotic Microangiopathies (1)
Neoplasms by Histologic Type (10) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Glandular and Epithelial (10) · Neoplasms, Nerve Tissue (10) · Neoplasms, Neuroepithelial (10) · Neuroectodermal Tumors (10) · Neuroectodermal Tumors, Primitive (10) · Neuroectodermal Tumors, Primitive, Peripheral (10) · Neoplasms (9) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Behavior (1) · Behavioral Symptoms (1) · Blood Platelet Disorders (1)
Cyclophosphamide (3) · Irinotecan (3) · Temozolomide (3) · dinutuximab (3) · Carboplatin (2) · Doxorubicin (2) · Etoposide (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Ifosfamide (2) · Radiotherapy (2) · Vincristine (2) · naxitamab (2) · Busulfan (1) · Cisplatin (1) · Colony-Stimulating Factors (1)
Memorial Sloan Kettering Cancer Center (3) · Dana-Farber Cancer Institute (2) · Stephan Grupp MD PhD (2) · BeiGene (1) · Beijing Biotech (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Jagiellonian University (1) · Renaissance Pharma Ltd. (1) · Roberto Chiarle (1) · Shaare Zedek Medical Center (1) · St. Jude Children's Research Hospital (1) · University of California, San Francisco (1)
United States (9) · China (2) · Denmark (2) · France (2) · Germany (2) · Israel (2) · Spain (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · Finland (1) · Greece (1)
Brian Kushner, MD (3) · Kira Bona, MD, MPH (2) · Christine Higham, MD (1) · Claudia Pasqualini, MD PhD (1) · Iris Fried, MD (1) · Jacquelyn Crane, MD (1) · Lisa Wray, MD (1) · Sara Federico, MD (1) · Stephan A. Grupp, MD, PhD (1) · Susanne Baumeister, MD (1) · Walentyna Balwierz, Prof. (1)
2019 (1), 2025 (1), R37CA282041 (1)